



# Saving Lives Through Innovative Molecular Diagnostic Solutions

Corporate Update | January 2022

# Safe Harbor

---

This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; expectations for development of new or improved products and services; our strategies, positioning, resources, capabilities and expectations for future events or performance; and the anticipated benefits of our acquisitions, including estimated synergies and other financial impacts



# ABOUT MAINZ BIOMED



- **Mainz BioMed** – founded in Germany and aiming to become a leading provider of easy-to-use diagnostic solutions for patients everywhere.
- Early identification of cancer saves lives.  
To be effective, sample collection needs to be simple, readily available, and affordable.
- We develop innovative products and product candidates that quickly and easily identify the early onset of several leading deadly conditions – such as colorectal (“CRC”) and pancreatic cancer.
- Our goal is to place effective solutions where they need to be...  
In your hands.

# INVESTMENT HIGHLIGHTS

## A Blockbuster Early Detection Test for Colorectal Cancer



**Significant Impact:** Colorectal cancer is the 2<sup>nd</sup> most lethal cancer in the US, but also highly preventable; with early detection providing 5-year survival rates above 90%.<sup>1</sup>



**Revenue Generating:** ColoAlert is CE-IVD marked and is approved for sale in Europe. European sales provide near-term revenue potential, while we prepare our entry into the US market.



**Upside Potential:** We plan on starting the FDA process shortly after our public listing. Recent FDA guidance recommends colorectal cancer screening for everyone over the age of 45, which translates to market potential of over 52 million tests per year.<sup>(a)</sup>

### Ease of Use

Non-invasive test, which can be taken at home, with rapid response of 92% specificity and 85% sensitivity. Designed to be easier to administer than Exact Science's ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy.<sup>(b)</sup>

### Attractive Valuation

Our closest peer, Exact Sciences (NASDAQ: EXAS) - ColoGuard product is only sold in the US - has a market cap of approximately 13 billion USD. Mainz Biomed has a fraction of this valuation.<sup>(b)</sup>

### Experienced Management

Seasoned and experienced management, board & advisors with particular skill sets in commercializing and monetizing medical diagnostics at some of the largest medical companies in the world.

<sup>1</sup>Colorectal cancer is the second leading cause of cancer death in the US – [Cancer.org](https://www.cancer.org)

<sup>(a)</sup> See page #6

<sup>(b)</sup> See page #10





Clinical laboratory tests save costs and lives by enabling early detection and prevention of disease.

Patients with cancers and other conditions are living longer and enjoying better health because of medical revolutions in diagnostic technology.

At its center are genetic and genomic tests that identify the unique genetic profile of individual patients or their disease and allow physicians to tailor treatment to those unique characteristics.



\*Dollinger MM et al. (2018), ClinLab 64 (10), 1719-1730; internal data comparing ColoAlert to FIT.

NOTE: the globally most-used non-invasive test for screening programs. Fecal immunochemical test (FIT) is a screening test for hidden blood in the stool, which can be an early sign of cancer. FIT only detects human blood from the lower intestines. Blood in stool is often a late-stage sign.

<sup>1</sup>Colorectal cancer is the second leading cause of cancer death in the US – [Cancer.org](https://www.cancer.org)

<sup>2</sup>5-Year Survival rate 91% at Stage A – 2018 American Cancer Society Report

<sup>3</sup>Predicted deaths from CRC in USA – [Cancer.org](https://www.cancer.org).



†Approved for sale in EU

**ColoAlert detects tumors better than the Fecal Immunochemical Test (FIT)\***

- Higher patient acceptance than FIT test.\*
- Accurate, non-invasive, simple, safe diagnostic solution to increase patient compliance.
- Proposed partnerships with clinical labs aims to speed test collection & results.
- Designed to offer significant advantages compared to our major competitor ("ColoGuard"), manufactured by Exact Sciences Corp.

**Colorectal Cancer  
is the #2nd  
leading killer  
(Men & women  
combined)<sup>1</sup>**

**52,980 deaths  
due to CRC in  
USA  
(2021)<sup>3</sup>**

**5-year  
survival rate  
>90%  
(If detected at stage  
A).<sup>2</sup>**

# ABOUT COLORECTAL CANCER

Market Opportunity

Recent FDA decisions suggest that screening should be conducted once every three years starting at age 45.

Currently, there are 112 Million Americans aged 50+, a total that is expected to increase to 157 million within 10 years.<sup>8</sup>

**37 Million**

Tests per year  
in the US

estimated potential:  
112M pop. ÷ 3 (years)  
@100% compliance

**52 Million**

Tests per year  
within 10 years

estimated potential:  
157M pop. ÷ 3 (years)  
@100% compliance

Risk group patients: BMI > 30. High-fat/-sugar nutrition, consumption of red/processed meat, consumption of tobacco/alcohol, chronic bowel diseases, breast cancer, diabetes mellitus type 2, etc.<sup>7</sup>

Screenings  
should be done  
once every 3 years

**19 million**

Colonoscopies  
each year in USA<sup>4</sup>

**~38.8%**

Age 50 to 75 have  
never been  
screened (in USA)<sup>5</sup>

**\$3.7B**

Market  
Opportunity<sup>6</sup>

**52,980**

Expected deaths  
in US, 2021<sup>3</sup>

<sup>3</sup>Predicted deaths from CRC in USA – [Cancer.org](https://www.cancer.org).

<sup>4</sup>19 million colonoscopies annually – [iDataResearch.com](https://www.dataresearch.com)

<sup>5</sup>Percentage of screening in USA – [Centers for Disease Control & Prevention](https://www.cdc.gov/disease/prevention)

<sup>6</sup>Internal calculation: 112M individuals/3 X \$100 USD = \$3.7B USD yearly

<sup>7</sup>Colorectal cancer risk factors – [Cancer.org](https://www.cancer.org).

<sup>8</sup>Population Reference bureau – [prb.org](https://prb.org)

## Simple, Fast, Accurate and Non-Invasive

- A PCR-based CRC early detection stool test
- Up to 60% fewer missed cases compared to fecal immunochemical test (FIT)<sup>9</sup>
- Non-invasive, no preparation or sedation, no time off work
- 98% patient satisfaction – Easy product to use<sup>10</sup>
- Designed to offer affordable CRC screening solutions



Europe's  
answer to  
Exact Sciences'  
ColoGuard



Patients receive a simple kit that includes instructions, a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results. IT'S THAT EASY.

visit [www.coloalert.com](http://www.coloalert.com)



Approved for sale in the European Union

<sup>9</sup> Comparing ColoAlert sensitivity with FITs (Gies et al. Gastroenterology 154/2018)  
<sup>10</sup> 98% overall satisfaction with ColoAlert in our internal customer survey.

## Strategic Roll Out

***Aiming to become the leading global brand for CRC detection through extensive US and European market partnerships***

### THE COMPETITION'S APPROACH...

The largest U.S. provider independently markets and distributes its product directly. All nationwide samples must come from, and be returned to, a single corporate laboratory – a time-consuming process.

**Mainz BioMed intends to develop and leverage scalable dissemination through a collaborative partner program**

#### PARTNERSHIPS:

Large lab chains incentivized to support sales & marketing efforts to physician clients & consumers.

#### RELATIONSHIPS:

Established regional and national labs offer existing client relationships (i.e.: physicians, clinics, hospitals, universities, government institutions, health organizations, etc).

#### PROFITABILITY:

ColoAlert is designed for profitability, rapid commercial uptake, and broad consumer acceptance.

#### PROTECTION:

Mainz BioMed protects its intellectual property through trade secrets to control all critical reagents, processes and formulations.






## Priority Rollout Markets

# ColoAlert launches from Germany... to Europe and America

- Expansion into EU markets is aligned with early-stage plans for American market entry.
- Upon FDA approval, Mainz BioMed plans to offer ColoAlert CRC screening test kits to national reference labs and major health institutions in the USA.
- Mainz BioMed is carefully evaluating FDA requirements to ensure an expedited strategy is aligned with future clinical, regulatory and related guideline requirements.
- Key clinical studies will be co-located in the US and abroad to meet the requirements set by FDA for a screening application.



Exact Sciences, the makers of ColoGuard, offers the only other competitive product using similar technology.

Other sector companies promote testing for CRC but are using standard tests like FIT or occult blood testing.

Currently, Exact Sciences (NASDAQ: EXAS) has a market cap of ~\$13.7 billion.\*

Company	Exact Sciences Corporation
Exchange & Ticker	Nasdaq: EXAS
Market Capitalization	\$13.7B
Share Price	\$80.01
52 Week Range	\$80.01 - \$159.54
Avg. Volume	1,653,703

\*Yahoo! Finance, January 4, 2022

## Comparable findings to 10,000 patients in ColoGuard study\*\*

\*\* Imperiale et al. N Engl J Med 4/2014

	SENSITIVITY	SPECIFICITY
ColoAlert	85 %	92 %
ColoGuard** (based on separate study results)	92 %	87 %

ColoAlert targets lower cost than ColoGuard

ColoAlert has 3 out of 4 biomarkers identical to ColoGuard

ColoGuard requires significantly larger stool samples

ColoGuard is reimbursed @ about \$500 in USA

**Sensitivity** is the ability of a test to correctly identify those with the disease (true positive rate), whereas test **specificity** is the ability of the test to correctly identify those without the disease (true negative rate).

### INDEPENDENT MULTI-CENTER CASE COHORT STUDY

- Performed by the University Hospitals in Leipzig & Halle-Wittenberg, Germany.
- 18 study centers
- 566 patients
- Reference method: Colonoscopy
- Published as: Dollinger MM et al. Clin Lab 10/2018

### **PANCALERT** *In early research stage*

- As GenX individuals age into their 40's and 50's they become part of the age group recommended to begin testing for CRC and more.
- Mainz BioMed is currently developing proprietary genetic testing methods for pancreatic cancer.

THE WORLD'S FIRST  
EARLY DETECTION  
PANCREATIC CANCER  
SCREENING TEST based on  
real-time PCR-based  
detection of biomarkers in  
stool samples.

- Fighting what could soon become the world's second most deadly cancer.\*
- Convenient stool test for at-home use.
- Potential for over 50 million tests per year in Europe alone
- Supported by federal grant from Germany's Federal Ministry for Education and Research.
- Cost of goods sold (COGS) & reimbursement analogous to ColoAlert program.

\*<https://www.pancan.org/press-releases/pancreatic-cancer-still-on-path-to-become-second-leading-cause-of-cancer-related-death-in-u-s-by-2020/>



# RECENT ANNOUNCEMENTS – SINCE OUR IPO NOVEMBER 4, 2021

## CORPORATE NEWS

MAINZ BIOMED APPOINTS FORMER ROCHE DIVISION PRESIDENT HEINER DREISMANN TO STRATEGIC ADVISORY BOARD

MAINZ BIOMED APPOINTS DR. SOREN THESTRUP-NIELSEN M.D. TO STRATEGIC ADVISORY BOARD

MAINZ BIOMED APPOINTS KAREN RICHARDS AS VICE PRESIDENT, REGULATORY AFFAIRS TO LEAD US FDA APPROVAL PROCESS

MAINZ BIOMED TO EXHIBIT COLOALERT AT MEDICA 2021, THE WORLD'S LARGEST MEDICAL TRADE FAIR


MAINZ BIOMED LAUNCHES ECOMMERCE STORE FOR COLOALERT TO ASSIST PATIENT ACCESS DURING COVID-19 PANDEMIC

MAINZ BIOMED APPOINTS MICHELE PEDROCCHI, FORMER HEAD OF ROCHE DIAGNOSTICS BUSINESS DEVELOPMENT, TO STRATEGIC ADVISORY BOARD

MAINZ BIOMED EXPANDS COLOALERT COMMERCIALIZATION WITH GANZIMMUN DIAGNOSTICS IN EUROPE

MAINZ BIOMED ESTABLISHES PARTNERSHIP WITH PRECISION FOR MEDICINE TO SUPPORT COLOALERT'S U.S. REGULATORY AND COMMERCIAL STRATEGY

MAINZ BIOMED ACQUIRES EXCLUSIVE RIGHTS TO NOVEL MRNA BIOMARKERS







**Guido Baechler**  
CEO & Director

- 30 years of global experience leading public & private life science companies with sustained revenue and EBITDA growth.
- Founded Berkeley Life science Advisors, a diagnostic and life science start-up consulting firm.
- Former CEO at SummerBio, a leading high throughput COVID testing laboratory.
- Former President & CEO at Singulex, Inc. Alameda California – raised over \$180M through multiple financings.
- Former Roche molecular diagnostics executive, leading global program management.



**William Caragol**  
CFO

- 30 years of experience working with growth stage technology companies.
- Ex-Board Chair of Thermomedics, Inc., a privately held medical diagnostic equipment company.
- Director & Audit Committee Chair at Greenbox POS (NASDAQ: GBOX) a financial tech company.
- Former Chairman & CEO of PositiveID, a holding company in the fields of bio detection systems and molecular diagnostics.
- Served as Director, Executive VP, COO and CFO of Hawaiian Springs LLC natural spring artesian bottled water company.
- Member of the American Institute of Certified Public Accountants.



**Moritz Eidens, PhD**  
CSO & Director

- Founded PharmGenomics GmbH in 2008 focused on the development of innovative methodologies for the detection of genetic variants.
- Led PharmGenomics as co-CEO and CSO since 2008.
- As CSO at PharmGenomics, responsible for the research and development of several innovative products.
- Managed several national and international consortial grant projects with large industrial or academic partners.
- Responsible for various financing rounds of PharmGenomics GmbH with national and international well reputed Banks such as KfW, Bonn, Germany and diverse business angels.



**Philipp Freese**  
COO

- Seasoned executive managing growth stage companies.
- Co-led Pharmgenomics since as co-CEO and commercial managing director responsible for marketing, sales, operations, legal affairs and finance since 2015.
- Responsible for the marketing and commercialization of ColoAlert in Germany and some selected other European countries.
- Established first customer traction in Germany and raised corresponding investments.
- Responsible for various financing rounds of PharmGenomics GmbH with national and international well reputed Banks such as KfW, Bonn, Germany and diverse business angels.



**Dr. Heiner Dreismann**  
Strategic Advisor

- Former President and **CEO of Roche Molecular Systems**, Pleasanton, California (2000-2006).
- Past member of Roche's Global Diagnostic and Executive Committee, and head of global business development,
- Over 35 years of experience in the life sciences and health care industries.
- A pioneer in the early adoption of polymerase chain reaction (PCR) technique, one of the most ubiquitous technologies in molecular biology and genetics research today.
- Joined F. Hoffmann La Roche AG in 1985 and served as head of manufacturing for microbiological diagnostics, head of R&D microbiological diagnostics and head of the Business Area Microbiology.
- Led the PCR Business Unit for Europe and strategic planning for PCR diagnostics since acquisition (1991).
- Currently serves on the boards of several public and private life sciences and health care companies in the United States, Europe and Israel.



**Soren Thesthrup-Nielsen M.D.**  
Clinical Advisor

- Proven track record as a board & management advisor to numerous companies in the diagnostics and medical technology industry.
- 6 years with **Danaher Corporation** in senior executive management and corporate development for companies such as **Radiometer Medical and Beckman Coulter Diagnostics**.
- Executive experience leading diagnostics acquisition projects and medical device private equity investments.
- Former chairman & CEO of Althea Group, a group of healthcare companies owned by Permira Advisors, one of the world's leading private equity firms.
- Served on the board on Oncimmune Ltd., a UK-based lung cancer screening company with operations in the US.
- Currently Board Chair at Cathvision and VitalBeats, both Denmark-based health informatics companies.



**Dr. Michele Pedrocchi**  
Strategic Advisor

- Over 25 years of global experience in Health Care and Life Sciences holding leadership roles in corporate strategy, business development, strategic marketing, trial management and commercial execution
- Former Global Head of Strategy and Business Development and member of the **Executive Committee of Roche Diagnostics**
- Former country and regional General Manager in emerging and mature markets
- Instrumental role in establishing polymerase chain reaction (PCR) as a routine diagnostics methodology in Europe and in venturing into digital health solutions
- Pioneering role in introducing patient selection for targeted oncology treatments through Companion Diagnostics (CDx)
- Currently acting as Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies



# Mainz Biomed aims to become a leader in the multi-billion-dollar colorectal cancer diagnostics market



ColoAlert Holds Potential as a Blockbuster Early Detection Test for Colorectal Cancer.



This is Europe's answer to Exact Sciences' (~\$14 billion market cap) ColoGuard product.



Designed for profitability, rapid commercial uptake, and broad consumer acceptance.



Mainz BioMed protects its intellectual property through trade secrets to control all critical reagents, processes and formulations.



Mainz BioMed is developing proprietary genetic testing methods for pancreatic cancer.



THANK YOU



CORPORATE PRESENTATION | JANUARY 2022

Mainz Biomed B.V.  
Robert-Koch-Straße 50  
55129 Mainz, Germany

Tel: +49 (0) 6131 / 55428-68  
Inquiries: [info@mainzbiomed.com](mailto:info@mainzbiomed.com)